Amgen paying Arrowhead for traits to develop cardiovascular drugs
Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
Investing money in Ceres requires act of blind faith
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ceres corn traits do not require USDA oversight
Thousand Oaks ag-biotech company Ceres said the U.S. Department of Agriculture told the company Feb. 17 that several corn traits Ceres developed do not need to be regulated under a USDA mandate. For years, Ceres developed genetically modified crops for use in biofuels. Last June, the company switched its focus to developing genetically modified crops Read More →
